Literature DB >> 31724462

miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway.

Anfeng Si1, Longqi Wang2, Kun Miao3, Rongrong Zhang4, Huiyu Ji1, Zhengqing Lei5, Zhangjun Cheng5, Xiangchun Fang1, Baobing Hao1.   

Abstract

Liver cancer stem cells contribute to tumorigenesis, progression, recurrence and drug resistance of hepatocellular carcinoma (HCC). However, the underlying mechanism for the propagation of liverCSCs is not fully understood yet. Here we show that miR-219 is upregulated in liver CSCs. Knockdown of miR-219 attenuates the self-renewal and tumorigenicity of liver CSCs. Conversely, miR-219 overexpressing enhances the self-renewal and tumorigenicity of liver CSCs.Mechanistically,miR-219 downregulates E-cadherin via itsmRNA 3'UTR in liver CSCs. The correlation between miR-219 and E-cadherin is validated in human HCC tissues. Furthermore, the miR-219 expression determines the responses of hepatoma cells to sorafenib treatment. Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.Abbreviations: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.

Entities:  

Keywords:  E-cadherin; Hepatocellular carcinoma; liver cancer stem cell; miR-219; sorafenib

Year:  2019        PMID: 31724462      PMCID: PMC6927721          DOI: 10.1080/15384101.2019.1691762

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  31 in total

1.  Inhibition of didscoidin domain receptor 1 reduces epithelial-mesenchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines.

Authors:  Reza Azizi; Zahra Salemi; Faranak Fallahian; Mahmoud Aghaei
Journal:  J Cell Physiol       Date:  2019-04-08       Impact factor: 6.384

2.  Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.

Authors:  Xiao-Feng Li; Cheng Chen; Dai-Min Xiang; Le Qu; Wen Sun; Xin-Yuan Lu; Teng-Fei Zhou; Shu-Zhen Chen; Bei-Fang Ning; Zhuo Cheng; Ming-Yang Xia; Wei-Feng Shen; Wen Yang; Wen Wen; Terence Kin Wah Lee; Wen-Ming Cong; Hong-Yang Wang; Jin Ding
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

3.  Inhibitory effect of bufalin combined with Hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells.

Authors:  Xia Sheng; Xiaoting Sun; Kang Sun; Hua Sui; Jianmin Qin; Qi Li
Journal:  Int J Oncol       Date:  2016-08-22       Impact factor: 5.650

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

5.  MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.

Authors:  Na Huang; Jing Lin; Jian Ruan; Ning Su; Ruzhai Qing; Feiye Liu; Benfu He; Chengwei Lv; Dayong Zheng; Rongcheng Luo
Journal:  FEBS Lett       Date:  2012-02-20       Impact factor: 4.124

6.  Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.

Authors:  Angela Gauthier; Mitchell Ho
Journal:  Hepatol Res       Date:  2012-11-12       Impact factor: 4.288

7.  Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4.

Authors:  Liang Li; Jing Tang; Baohua Zhang; Wen Yang; Miyang LiuGao; Ruoyu Wang; Yexiong Tan; Jianling Fan; Yanxin Chang; Jing Fu; Feng Jiang; Caiyang Chen; Yingcheng Yang; Jin Gu; Dingming Wu; Linna Guo; Dan Cao; Hengyu Li; Guangwen Cao; Mengchao Wu; Michael Q Zhang; Lei Chen; Hongyang Wang
Journal:  Gut       Date:  2014-02-26       Impact factor: 23.059

8.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

Review 9.  Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Marta B Afonso; Pedro M Rodrigues; André L Simão; Rui E Castro
Journal:  J Clin Med       Date:  2016-03-03       Impact factor: 4.241

10.  MicroRNA-219-5p Promotes Tumor Growth and Metastasis of Hepatocellular Carcinoma by Regulating Cadherin 1.

Authors:  Jing Yang; Yuan-Yuan Sheng; Jin-Wang Wei; Xiao-Mei Gao; Ying Zhu; Hu-Liang Jia; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Biomed Res Int       Date:  2018-05-15       Impact factor: 3.411

View more
  2 in total

Review 1.  Advances in Liver Cancer Stem Cell Isolation and their Characterization.

Authors:  Lu Liu; Jürgen Borlak
Journal:  Stem Cell Rev Rep       Date:  2021-01-11       Impact factor: 5.739

Review 2.  Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.

Authors:  Zhi Zeng; Qiliang Lu; Yang Liu; Junjun Zhao; Qian Zhang; Linjun Hu; Zhan Shi; Yifeng Tu; Zunqiang Xiao; Qiuran Xu; Dongsheng Huang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.